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Objective: In this study, we compared the pharmacokinetic profiles of 5-fluorouracil (5-FU),
tegafur, 5-chloro-2,4-dihydroxypyridine (CDHP) and potassium oxonate (Oxo) after adminis-
tration of S-1 at 35 or 40 mg/m2 bid for 28 consecutive days, in Cycles 1 and 3, in patients
with advanced gastric cancer.
Methods: Three patients were enrolled for each dosage. S-1 dosage was assigned based on
body surface area (BSA), which is different from the Japanese dosing system. The median
daily dose per BSA was 76 mg/m2, ranging from 70 to 88 mg/m2.
Results: Plasma levels of 5-FU, tegafur, CDHP and Oxo at 4 h post-dose reached steady-
state on day 8. The estimated steady-state level was dependent on S-1 dosage. There were
no intercyclic differences of pre-dose and 4 h post-dose levels between Cycles 1 and 3,
implying no cumulative effect of S-1 was shown probably due to 2-week drug-resting period.
Pharmacokinetic profiles on day 28 were similar to previous Japanese report. Cmax and
AUC0–48h values of each S-1 component increased depending on S-1 dosage.
Pharmacokinetic parameters were not correlated with tumor response or toxicity.
Conclusions: We suggest that these pharmacokinetic profiles of Asian population could
provide a basis for schedule optimization and for additional studies on interaction with other
antitumor drugs.
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INTRODUCTION
5-Fluorouracil (5-FU) is a mainstay of chemotherapy in
advanced gastric cancer. Bolus injection of 5-FU resulted in
a 13–20% of response rate and its protracted continuous
infusion (PCI) resulted in 18–26% of response rate (1–3).
Although few full-scale trials have been conducted to
directly compare these two schedules of 5-FU treatment in
gastric cancer based on its association with less myelosup-
pression and diarrhea, PCI is considered an acceptable refer-
ence treatment (4,5). However, 5-FU concentration in
plasma signiﬁcantly varies with PCI schedule. Also, 90%
of administered 5-FU is metabolized mainly to
a-ﬂuoro-b-alanine, thus abolishing its antitumor effect.
Finally, dihydropyrimidine dehydrogenase (DPD) is the
main factor affecting the 5-FU chemosensitivity.
S-1 is an oral ﬂuoropyrimidine that was developed to
mimic PCI of 5-FU. High 5-FU levels were maintained both
in plasma and in tumor tissues, with reduced gastrointestinal
toxicity, by combining tegafur with two biomodulators,
5-chloro-2,4-dihydroxypyridine (CDHP) and potassium
oxonate (Oxo). Tegafur is converted to 5-FU in the liver by
cytochrome P4502A6. CDHP inhibits the catabolism of
5-FU by inhibiting DPD activity. The other component,
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Oxo, blocks phosphorylation of 5-FU in the intestine to
reduce gastrointestinal toxicity (6,7). In the initial phase II
trials conduced in Japan, S-1 monotherapy showed such a
promising tumor response in gastric cancer that it was com-
parable to combination chemotherapies (8–10). However,
subsequent studies did not reproduce this initial high tumor
response but demonstrated differences in drug metabolism
and toxicity among Japanese, USA and European popu-
lations. These data necessitated the evaluation of population-
speciﬁc pharmacokinetic proﬁles to in-depth understand the
ethnic differences and the pharmacologic property of S-1
(11–13). We conducted a multi-institutional phase II study
of S-1 monotherapy in advanced gastric cancer, which is the
ﬁrst in a non-Japanese Asian population (14). The study pro-
ceeded with two dosage levels of S-1, 35 and 40 mg/m2, and
pharmacokinetic evaluation was planned along with the
study for the purpose of obtaining further information on S-1
in Korean population.
Our aims here are (i) to investigate the changes in the
plasma level of S-1 in a treatment cycle; (ii) to obtain phar-
macokinetic proﬁles after 28 days of consecutive adminis-
tration to see the dosage effect and intercyclic differences
with repetitive treatment of S-1 and ﬁnally (iii) to correlate
with toxicity and antitumor activity.
PATIENTS AND METHODS
PATIENTS
Patients were enrolled when they have histologically con-
ﬁrmed gastric adenocarcinoma with inoperable or metastatic
disease; age 18 years; performance status 2 according to
the criteria of Eastern Cooperative Oncology Group; a life
expectancy of 3 months, no prior chemotherapy for
advanced disease (adjuvant chemotherapy should have been
completed at least 6 months before enrollment); bidimen-
sionally measurable lesions and adequate organ function
(hemoglobin 10 g/dl, leukocyte 4000/ml, platelets
100 000/ml, serum creatinine 1.5 upper limit of
normal (ULN), total bilirubin 1.25  ULN and serum ami-
notransferase 2.5  ULN). Patients were excluded if they
had other active malignancies, brain metastasis or severe
comorbid conditions. The protocol was approved by the
institutional review board, and written informed consent was
obtained from patients according to the institutional
regulation.
TREATMENT PLAN
Three patients were allocated to 35 mg/m2 group, and
another three patients were allocated to 40 mg/m2 group. S-1
was administered twice a day within 1 h of breakfast and
supper for 28 consecutive days. This was followed by a
14-day resting period. Dosage was calculated according to
body surface area (BSA), which was different from
Japanese dosing system (15). Planned dose intensity was
327 mg/m2/week for the 35 mg/m2 group, and 373 mg/m2/
week for the 40 mg/m2 group. The schedule was repeated
until disease progression, unacceptable toxicity or patient’s
withdrawal of consent. Imaging studies for tumor response
were performed after each cycle, and tumor response was
measured according to the World Health Organization (WHO)
criteria. Adverse events were recorded every week and graded
according to the NCI-common toxicity criteria (version 2.0).
PHARMACOKINETIC STUDY
A pharmacokinetic study was performed in Cycles 1 and
3. In a treatment cycle, blood samples were collected in
heparinized tube immediately before and 4 h after doses on
days 1, 8 and 15. And on day 28, blood was collected before
as well as 1, 2, 3, 6, 8, 10, 14, 24 and 48 h after the last
administration of S-1. Plasma was isolated and stored
at 2808C until analysis. Urine samples were collected 12 h
before the last dose of S-1 and for the periods of 0–6, 6–12,
12–18 and 18–24 h after the last dosage of S-1. After esti-
mation of the total urine volumes, 10 ml aliquots were stored
at 2808C until analysis.
Analysis of tegafur, 5-FU, CDHP and Oxo was conducted
according to the method described by Matsushita et al.
(16,17). Brieﬂy, tegafur was extracted with dichloromethane
from each sample and analyzed using high-performance
liquid chromatography equipped with an UV absorption
spectrophotometer. 5-FU and CDHP were extracted with
ethyl acetate. Oxo was separately extracted using a solid
extraction column. They were analyzed using a negative-ion
chemical ionization gas chromatography/mass spectropho-
tometer. The lower measurable limit of plasma levels for
tegafur, 5-FU, CDHP and Oxo was 10, 1, 2 and 1 ng/ml,
respectively. The pharmacokinetic parameters were derived
using non-compartmental methods with ‘WinNonlin
Professional’ version 5.0 (Pharsight Corp., Mountain View,
CA, USA). The pharmacokinetic parameters included the
determination of maximum plasma concentration (Cmax),
time to maximum plasma concentration (Tmax), area under
the plasma concentration-versus-time curve from time 0 to
48 h (AUC0– 48h) and plasma elimination half-life (T1/2).
Pharmacokinetic analysis for the S-1 constituents in urine
included the determination of the amount excreted at each
collection interval and the cumulative amount excreted over
a 24 h period.
RESULTS
PATIENT CHARACTERISTICS
Three patients were enrolled for each dosage group of 35
and 40 mg/m2. The six patients consisted of ﬁve men and
one woman. Ages were between 28 and 66 years, and the
median age was 61 years old. Three patients received prior
gastrectomy. The median hemoglobin level was 11.3
(range: 10.0–13.5 g/dl). The median BSA was 1.66 m2
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(range: 1.27–1.88 m2) and the median actual daily dose
administered was 125 mg (range: 100–140 mg). The median
daily dose divided by BSA was 71 mg/m2 (range:
69–73 mg/m2) for 35 mg/m2 group and 83 mg/m2 (range:
79–88 mg/m2) for 40 mg/m2 group. All the patients had
normal baseline range of creatinine clearance, of which the
median value was 80 ml/min (range: 68–112 ml/min).
CHANGE OF THE PLASMA LEVEL OF 5-FU IN ONE TREATMENT
CYCLE
Figure 1 shows the changes in the mean plasma level of
5-FU, the active metabolite of tegafur, measured on days 1,
8, 15 and 28 in Cycles 1 and 3. 5-FU readily appeared in
plasma from day 1. With 35 mg/m2, the 4 h post-dose
plasma level of 5-FU after single dose of S-1 was 56+9 ng/ml.
At 40 mg/m2, the 5-FU plasma level increased to 191+
94 ng/ml. The pre-dose (trough) and 4 h post-dose 5-FU
levels were similar to one another on days 8, 15 and 28, indi-
cating that 5-FU concentration in plasma reached the
steady-state level on day 8. Also, the estimated steady-state
level on day 8 was also dependent on dosage. At 35 mg/m2,
the mean steady-state 5-FU level was 108+ 21 ng/ml. At
40 mg/m2, it was 176+ 114 ng/ml. There were no signiﬁcant
differences in pre-dose and 4 h post-dose plasma levels
between Cycles 1 and 3, implying that there were no inter-
cyclic cumulative effect of 5-FU.
CHANGE IN PLASMA LEVELS OF TEGAFUR, CDHP AND OXO IN
ONE TREATMENT CYCLE
Figure 2 shows changes in the mean plasma levels of the
three components of S-1 (tegafur, CDHP and Oxo) measured
in Cycles 1 and 3. At a dose of 35 mg/m2, tegafur plasma
concentration was 4000 ng/ml at each pre-dose and 4 h
measurement on days 8, 15 and 28, indicating that its plasma
concentration reached the steady-state which was around
4000 ng/ml. On the contrary, at 40 mg/m2, both pre- and
post-dose levels kept increasing as S-1 administration contin-
ued through day 28, reaching as high as 6554+ 2344 ng/ml.
This suggests a dose-related accumulation of tegafur at
40 mg/m2.
CDHP and Oxo also reached steady-state on day
8. Although unclear for CDHP, Oxo plasma levels correlated
with S-1 dosage. Moreover, like the case of 5-FU, there were
no deﬁnite inter-cyclic differences in plasma levels between
Cycles 1 and 3 for tegafur, CDHP and Oxo.
PHARMACOKINETICS AFTER 28 DAYS OF CONSECUTIVE
ADMINISTRATION
Pharmacokinetic parameters of tegafur, 5-FU, CDHP and
Oxo measured after the last dose on day 28 are summarized
in Fig. 3 (also in Supplementary material, Table S1). At
35 mg/m2, mean Cmax for tegafur, 5-FU, CDHP and Oxo
was 4484+ 1231, 91+ 23, 191+ 14 and 33+ 1.0 ng/ml,
respectively. Mean AUC0–48h was 99 907+ 38 999, 750+
120, 1359+ 373 and 337+ 80 ng h/ml, respectively.
Besides, the mean Cmax of 5-FU and three S-1 components
increased with S-1 dosage. AUC was also dependent on
dosage, but 5-FU AUC0– 48h increased only marginally to
767+ 194 ng h/ml (3%). 5-FU was eliminated from plasma
with mean T1/2 values that did not markedly vary with the
dosage.
Mean AUC0–48h for 5-FU and CDHP increased in Cycle
3 compared with Cycle 1, whereas other parameters showed
little inter-cyclic changes. This increase in 5-FU and CDHP
might imply a correlation between DPD inhibition by CDHP
Figure 1. Changes in the average plasma level of 5-FU measured on days 1, 8, 15, and 28 after S-1 administration.
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Figure 2. Change in the average plasma level of S-1 components measured on days 1, 8, 15 and 28 after S-1 administration in Cycle 1: (A) tegafur, (B)
CDHP and (C) Oxo. CDHP, 5-chloro-2,4-dihydroxypyridine; Oxo, potassium oxonate.
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and 5-FU levels after S-1 administration. The urinary
excretion of tegafur, 5-FU, CDHP and Oxo within 24 h after
administration of the last dose on day 28 was 37.3+ 15.0,
17.1+ 4.3, 154.5+ 19.7 and 5.4+ 1.1 mg, respectively.
There was no correlation of S-1 urinary excretion with its
dosage or cycle.
CORRELATION WITH TOXICITY AND ANTITUMOR EFFECT
Two patients underwent 3 cycles of treatment, three patients
underwent 4 cycles of treatment and the remaining patient
underwent 10 cycles. Two patients—from two in the
40 mg/m2 group—showed partial responses, whereas the
disease was stable in the remaining patients. Also three
patients—two in the 35 mg/m2 group and one in the 40 mg/
m2 group—suffered Grade 3 anemia during treatment. We
investigated the correlation between treatment outcome—
toxicity and antitumor activity—and pharmacokinetic par-
ameters. With Spearman’s correlation coefﬁcient, neither
Cmax nor AUC correlated with toxicity or response.
DISCUSSION
Blood pharmacokinetics of 5-FU reﬂect those in tumors
(18). In addition, there exists a clinical correlation between
5-FU AUC and treatment outcomes (19,20). However,
reports on 5-FU plasma levels with PCI are inconsistent,
which is due to its high dependency on the activity of DPD.
S-1 was found to successfully allow an effect similar to that
of long-term PCI of 5-FU, and the combination of a CDHP
and tegafur makes the width of variation of the 5-FU plasma
level narrow (15).
We conducted a pharmacokinetic study of S-1, based on
the doses used in our previous multinational Phase II study,
which was the ﬁrst performed in non-Japanese Asian popu-
lation (14). We ﬁrst evaluated the changes in the 5-FU
plasma level during the treatment cycle. The non-toxic con-
centration of 5-FU is reported to be 195 ng/ml, and the
steady-state concentration (Css) of 5-FU correlates with inci-
dence of leucopenia (21). In the previous Japanese study of
S-1 pharmacokinetics, peak plasma levels were reached 3.5 h
after administration, which was the basis of our measuring
4 h post-dose level of 5-FU only once in this study (15).
However, our post-dose level 5-FU after a single adminis-
tration was only 56 ng/ml, which is half of that measured in
the Japanese study (15). We thought that this difference
seemed to be overcome by dose increment of S-1 to
40 mg/m2. At the dose of 40 mg/m2, we have attained the
highest dose intensity of S-1 (367 mg/m2/week) ever
reported in the Phase II trials. However, the 5-FU plasma
level was 181 ng/ml, which is still in the non-toxic range for
5-FU. This explains, at least partially, the favorable compli-
ance of our patients to S-1 and the low incidence of Grade 3
neutropenia in our trial (14).
Figure 3. Pharmacokinetic proﬁle of 5-FU and S-1 components measured on day 28 after the last dose of S-1: (A) tegafur, (B) 5-FU, (C) CDHP and
(D) Oxo.
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This low 5-FU level could be explained by two factors: (i)
low conversion from tegafur and (ii) low activity of CDHP.
CDHP attains its maximal concentration as early as 2 h in the
Japanese trial, and its 4 h post-dose level was still 100 ng/
ml. Although it would be hasty to infer a role for CDHP in
our patients from a simple extrapolation of the Japanese data,
we can at least think that general CDHP levels are not much
different between the two populations (22). However,
changes in the tegafur plasma level could provide a clue. The
mean post-dose level of tegafur after a single S-1 adminis-
tration was 1.68 mg/ml. In a Phase I/II study of a single
administration of UFT, which is another combination formula
with DPD inhibitor, and tegafur alone at 300 mg/body, the
tegafur plasma level was 13.7 and 12.3 mg/ml, respectively.
These levels are 8-fold higher than measured in our trial
(22). Considering that the overall average dose of S-1 (as
tegafur) was 63 mg/body, which was higher than Japanese
study (50 mg/body), our levels were only 5-fold against that
of UFT and tegafur. It indicates that the value of the plasma
tegafur is lower than expected. Therefore, failing to achieve
appropriate plasma level of tegafur could explain the low
plasma 5-FU levels seen in our patients.
In one treatment cycle, the plasma concentration of 5-FU,
CDHP and Oxo readily attained the steady-state levels on day
8, which was consistent with a previous study (23). Tegafur
increased in both trough and post-dose levels at the 40 mg/m2,
but it did not necessarily accompany the increase in 5-FU
level to the same extent. Taking the long half-life of tegafur
into account, the result may reﬂect the accumulation of S-1—
as the form of tegafur—and the saturation of the capacity to
convert tegafur to 5-FU—such as cytochrome P4502A6 at
40 mg/m2 of S-1 (24). The conversion level of our patients
would have been comparable to that of Japanese patients when
considering the alleged similar inter-ethnic proﬁle of cyto-
chrome P4502A6 polymorphisms in the two populations (25).
Many reports agree on the importance of evaluating
potential ethnic differences in the metabolism of S-1,
which lead to differential dose tolerance and toxicity.
Myelosuppression was the toxicity that has precluded dose
escalation in Japanese studies, whereas gastrointestinal and
skin toxicity were the features of western trials. In addition,
anemia was the unique toxicity encountered in a Korean
Phase II study (14). Regardless, maximum tolerated doses
were found to be higher in Asian studies than in western
studies, and Korean study obtained the highest dose intensity
ever reported with favorable compliance (14,26). Therefore,
it seemed no wonder that our pharmacokinetic behaviors of
S-1 and its components were more similar to those of
Japanese ﬁndings rather than to those of Americans at an
equivalent dose level of 35 mg/m2. Hoff et al. (12) noticed
that AUC of 5-FU were similar among various trials, but
those of tegafur were much higher in Japanese patients. This
is partially explained by aforementioned ethnic variation in
the cytochrome P450. Other authors speculated that this
difference came from apparent difference in exposure to
5-FU resulting from different total doses due to different
body sizes, as Japanese people have lower BSA than wes-
terns (27). Mean value of daily S-1 dose per BSA is 71 mg/
m2 in western patients and 76 mg/m2 in Japanese patients
(27). For Korean patients, this value increases to 83 mg/m2
at 40 mg/m2. These ﬁndings, which are further supported by
the present study, raised the question that pharmacogenomic
approaches accounts for the difference in pharmacologic be-
havior among various ethnic groups. For tegafur, a
dose-related increase in AUC was observed from 35 and
40 mg/m2 groups. However, AUC values of 5-FU and
CDHP did not so much as those for tegafur. Although this
observation may result from small absolute differences
between these dose levels, it adds another potential example
of saturated biotransformation of tegafur converting to 5-FU.
We demonstrated little changes in AUC or Cmax values of
tegafur and Oxo between Cycles 1 and 3. This implies that a
cumulative effect of S-1 is frivolous and that resting period
of 2 weeks would be a reasonable wash-out period.
However, we could notice the tendency that the mean AUC
values and half-life of 5-FU and CDHP increased in Cycle 3
at 40 mg/m2. This increase might demonstrate a correlation
between DPD inhibition by CDHP and 5-FU levels after S-1
administration. Allowing that all the patients maintained
creatinine clearance within normal range throughout the
entire treatment period, it may also suggest that the increas-
ing risk of toxicity is plausible as treatment cycles progress
in this dose level due to a cumulative effect of CDHP and
5-FU.
Although sample size is small, our data demonstrate that
pharmacokinetic behaviors of S-1 could not predict response
and toxicity, also consistent with previous reports (20). We
suggest that S-1 could be another target for pharmacoge-
netic/pharmacogenomic tools for future trials. To conclude,
this is the ﬁrst pharmacokinetic study performed in
non-Japanese Asian population that tested the highest dose
intensity ever obtained as S-1 monotherapy. Our data
demonstrate (i) the similar pharmacokinetic behaviors to the
Japanese population at equivalent dosage, (ii) possible satur-
ation of tegafur conversion to 5-FU at 40 mg/m2, (iii) negli-
gible cumulative effects at 35 mg/m2 between cycles and
ﬁnally (iv) the poor relationship of pharmacokinetic beha-
viors with clinical outcomes. We believe that our data could
provide a basis for schedule optimization of S-1 and for
additional pharmacokinetic studies on the interaction with
other antitumor agents for future clinical trial designs.
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Clinical Oncology Online.
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